A. Dona

发表

FoxO3a as a Positive Prognostic Marker and a Therapeutic Target in Tamoxifen-Resistant Breast Cancer

C. Giordano, D. Bonofiglio, F. Sotgia, 2019, Cancers.

Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting

J. Keats, C. Hofmeister, A. Krishnan, 2019, bioRxiv.

Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo

C. Hofmeister, A. Krishnan, F. Pichiorri, 2021, Molecular therapy oncolytics.

MiR-16 regulates crosstalk in NF-kB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages.

J. Keats, P. L. Bergsagel, C. Hofmeister, 2019, JCI insight.

Leveraging IFNγ/CD38 regulation to unmask and target leukemia stem cells in acute myelogenous leukemia

A. Krishnan, H. Vahed, F. Pichiorri, 2023, bioRxiv.

Bergapten induces metabolic reprogramming in breast cancer cells.

E. Cione, S. Aquila, D. Sisci, 2016, Oncology reports.

Ligand activated progesterone receptor B drives autophagy-senescence transition through a Beclin-1/Bcl-2 dependent mechanism in human breast cancer cells

S. Andò, D. Bonofiglio, M. Pellegrino, 2016, Oncotarget.

Proteasome inhibition enhances myeloma oncolytic reovirus therapy by suppressing monocytic anti-viral immune responses

A. Krishnan, H. Vahed, F. Pichiorri, 2022, medRxiv.

Immune Mediated Mechanisms of Resistance to Daratumumab

J. Keats, A. Krishnan, F. Pichiorri, 2018, Blood.

Design of Potent pan-IAP and Lys-Covalent XIAP Selective Inhibitors Using a Thermodynamics Driven Approach.

F. Pichiorri, L. Gambini, A. Salem, 2018, Journal of medicinal chemistry.

Androgens downregulate miR-21 expression in breast cancer cells underlining the protective role of androgen receptor

S. Andò, M. Pellegrino, P. Rizza, 2016, Oncotarget.

Bergapten induces metabolic reprogramming in breast cancer cells.

E. Cione, S. Aquila, D. Sisci, 2016, Oncology reports.